A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia
Keywords: Ovarian cancer; Gamma-secretase inhibitor; RO4929097; Notch; Phase II clinical trial;